Nolan Townsend, Lexeo Therapeutics CEO
October 30, 2024 03:29 PM EDT
R&D

Lex­eo shares ear­ly da­ta on Alzheimer’s gene ther­a­py 

Lei Lei Wu

News Reporter

Lex­eo Ther­a­peu­tics shared bio­mark­er da­ta from 15 pa­tients in a Phase 1/2 study of its gene ther­a­py for Alzheimer’s dis­ease. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

As­traZeneca Chi­na ex­ec probed by lo­cal au­thor­i­ties

Up­dat­ed: Lil­ly’s shares tank af­ter trim­ming rev­enue guid­ance. It al­so cut three as­sets

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

At­las of tu­mors re­veals in 3D how cells change in­to can­cer

A start­up backed by No­bel win­ner David Bak­er takes an AI twist on an­ti­bod­ies

Ab­b­Vie’s im­munol­o­gy block­busters make up for Hu­mi­ra sales drop in Q3

A service from the Financial Times